InflammaSkin®
HUMAN PSORIASIS SKIN MODEL TO TEST ANTI-INFLAMMATORY DRUGS
T CELL-DRIVEN KEY PSORIASIS FEATURES
InflammaSkin is currently the only ex vivo human psoriasis model T cell-driven with a Th17/Th1 phenotype.
PROPHYLACTIC & THERAPEUTIC
This psoriasis model can be used to assess prophylactic treatments for up to 7 days and therapeutic treatments for up to 4 days.
TOPICAL, SYSTEMIC & SUBCUTANEOUS
Anti-inflammatory response to anti-psoriasis drugs applied topically, diluted in the culture medium or subcutaneously administrated can be evaluated.
AVAILABLE AS A SERVICE
InflammaSkin model is available with or without adipose tissue as an in-house service.
InflammaSkin
The only ex vivo skin inflammation model with a psoriasis-like phenotype
Genoskin has developed a fully human T cell-driven ex vivo skin inflammation model based on the NativeSkin® explant technology. Resident T cells are activated in situ by injection into the skin. The injected skin models are then cultured for up to 7 days with a chemically-defined culture medium supplemented with a pro-inflammatory cytokine cocktail to induce Th17/Th1 T cell polarization.
InflammaSkin
A fully human model reproducing key psoriasis skin inflammation features
Histological analysis of InflammaSkin® model shows characteristic anomalies in the epidermis in contrast to non-inflamed NativeSkin® skin models. Epidermal activation is shown by the over-expression of the psoriasis-associated pro-inflammatory markers Keratin 16 (K16) and psoriasin (S100A7).
Histological characterization and expression of pro-inflammatory markers in InflammaSkin®
The analysis of cytokine levels in culture media at day 7 shows sustained secretion of IL-17A and IL-22 (IFN-γ and TNF-α as well as the lack of IL-4 expression, data not shown) compared to non-inflamed NativeSkin® skin models, supporting successful activation and differentiation of Th17/Th1 cells.
Release of pro-inflammatory cytokines from InflammaSkin® after 7 days of culture
A unique psoriasis model for anti-Th1/Th17 inflammatory drug testing
Daily topical application of betamethasone gel shows a restoration or preservation of epidermal integrity and viability after 7 days of prophylactic treatment when compared to untreated and normal skin (NativeSkin®), indicating anti-inflammatory effects. Further improvement is obtained with the daily topically applied PDE-4 cream.
Histological characterization and epidermal markers expression after prophylactic treatment with betamethasone dipropionate gel and PDE-4 inhibitor cream
A significant decrease of pro-inflammatory cytokines IL-17A and IL-22 release from InflammaSkin® following a 7-day prophylactic treatment with bethamethasone gel is observed compared to the vehicle gel. The same conclusion can be made with a 7-day prophylactic treatment with PDE-4 cream compared to the vehicle cream.
Release of pro-inflammatory cytokines from InflammaSkin® after 7 days of culture following prophylactic treatment
InflammaSkin
A fully human psoriasis model for prophylactic and therapeutic settings
InflammaSkin® model can be used to assess the efficacy of anti-inflammatory drugs targeting T cells as well as IL-17, IL-22 and TNF-α. Evaluation of efficacy can be performed following topical, systemic (dilution in the culture medium) or subcutaneous administration. Both prophylactic treatment (administration at day 0) and therapeutic treatment (administration at day 3) can be evaluated.
InflammaSkin is available as an in-house service.
InflammaSkin is available in two formats, without and with adipose tissue, for topical and subcutaneous administration.
| REFERENCE | DESCRIPTION | WORKING SURFACE | TOPICAL VOLUME | HYPODERMIS THICKNESS | INJECTION VOLUME | EX VIVO CULTURE DURATION | PLATE FORMAT | VOLUME OF MEDIUM/DAY |
|---|---|---|---|---|---|---|---|---|
| INF001 | InflammaSkin | 2.54 cm2 | 10-20µL | N/A | N/A | 7 days | 6 wells | 2mL |
| INF002 | Hypo-InflammaSkin | 2.54 cm2 | 10-20µL | 10mm | 25-45µL | 7 days | 6 wells | 2mL |
